<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002114</url>
  </required_header>
  <id_info>
    <org_study_id>215A</org_study_id>
    <secondary_id>CN9202D</secondary_id>
    <nct_id>NCT00002114</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides</brief_title>
  <official_title>A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Free Radical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of orally administered Procysteine with placebo in&#xD;
      HIV-infected patients who are receiving 1 of the following: (1) zidovudine (AZT) alone; (2)&#xD;
      didanosine (ddI) alone; (3) AZT plus ddI; or (4) AZT plus zalcitabine (ddC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients must receive treatment with antiretroviral nucleosides in addition to study&#xD;
      treatment. Patients are randomized equally into 1 of 3 outpatient dosage groups. Group 1&#xD;
      receives placebo; Group 2 receives a low dose of Procysteine; and Group 3 receives a higher&#xD;
      dose of Procysteine. Patients receive study treatment for 6 months (total duration of patient&#xD;
      participation is 30 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date>January 1994</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>125</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procysteine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
        Antiretroviral nucleosides (AZT alone, ddI alone, AZT plus ddI, or AZT plus ddC). Regimen&#xD;
        may be altered on or after Week 16.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Appropriate topical treatment or local radiotherapy for KS.&#xD;
&#xD;
          -  Treatment or prophylaxis for opportunistic infections, including pentamidine,&#xD;
             cotrimoxazole, acyclovir, fluconazole, etc., at the discretion of the investigator.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented serologic evidence confirming HIV infection.&#xD;
&#xD;
          -  Ability to participate in an outpatient study for at least 26 weeks.&#xD;
&#xD;
          -  Either:&#xD;
&#xD;
          -  (a) diagnosis of AIDS or AIDS-Related Complex (ARC) with CD4 count of 50 - 300&#xD;
             cells/mm3, or (b) CD4 count of 50 - 200 cells/mm3 and no symptoms of AIDS&#xD;
             (asymptomatic). (Note:&#xD;
&#xD;
          -  Patients whose AIDS-defining condition is Kaposi's sarcoma alone must have CD4 count&#xD;
             of 50 - 200 cells/mm3.)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Evidence of organ involvement with CMV and/or positive blood cultures for&#xD;
             Mycobacterium avium.&#xD;
&#xD;
          -  Life expectancy less than 26 weeks.&#xD;
&#xD;
          -  Malignancy or advancing Kaposi's sarcoma (KS) with advancing or unstable skin lesion,&#xD;
             or known or suspected visceral disease which requires systemic cytotoxic,&#xD;
             myelosuppressive chemotherapy.&#xD;
&#xD;
          -  Stage 2 or greater AIDS-dementia complex (ADC), defined as ability to perform basic&#xD;
             activities of self-care but inability to work or maintain more demanding aspects of&#xD;
             daily life as a result of an acquired decrease in cognitive CNS-related motor function&#xD;
             characteristic of ADC.&#xD;
&#xD;
          -  Psychological or emotional problems that prevent adequate compliance with study&#xD;
             therapy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Daily Vitamin C dosage greater than 1,000 mg or daily Vitamin E dosage greater than&#xD;
             100 units.&#xD;
&#xD;
          -  N-acetylcysteine, cysteine, or glutathione.&#xD;
&#xD;
          -  Any investigational drug.&#xD;
&#xD;
          -  Systemic chemotherapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of organ involvement with cytomegalovirus (CMV) and/or positive blood cultures&#xD;
             for Mycobacterium avium.&#xD;
&#xD;
          -  Intractable diarrhea, defined as greater than 4 bowel movements per day for at least 2&#xD;
             weeks.&#xD;
&#xD;
          -  History of seizures which have not been controlled with appropriate anticonvulsant&#xD;
             medications within the previous 6 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any investigational agent or biological response modifier (including interferon or&#xD;
             corticosteroids) within 1 month of study entry.&#xD;
&#xD;
          -  Use of erythropoietin (EPO), G-CSF, or GM-CSF within 28 days of randomization.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Active alcohol or drug abuse.&#xD;
&#xD;
        Required:&#xD;
&#xD;
        Antiretroviral nucleosides (AZT alone, ddI alone, AZT plus ddI, or AZT plus ddC) for at&#xD;
        least 3 months prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

